Trials / Unknown
UnknownNCT03611231
Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma
Chidamide Maintenance Treatment After Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed, Refractory or High-risk Lymphoma : a Prospective, Multi-centric, Single Arm, Open Label Phase II Clinical Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (estimated)
- Sponsor
- Peking University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Chidamide Maintenance Treatment After Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed, Refractory or High-risk Lymphoma : a Prospective, Multi-centric, Single Arm, Open Label Phase II Clinical Trial
Detailed description
Chidamide，a novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China. The aim of this study was to observe the efficacy and safety of Chidamide as Maintenance Treatment After Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed, Refractory or High-risk Lymphoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chidamide | Chidamide 20mg orally BIW. Treatment cycles are repeated every 4 weeks. |
Timeline
- Start date
- 2018-09-01
- Primary completion
- 2020-12-30
- Completion
- 2022-12-30
- First posted
- 2018-08-02
- Last updated
- 2018-08-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03611231. Inclusion in this directory is not an endorsement.